Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10286331 | 1.00 | P2RX7 (0.44) | P2RX7OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL10286334 | 1.00 | P2RX7 (0.44) | P2RX7OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL30979862 | 1.00 | P2RX7 (0.44) | P2RX7OPRL1KCNH2HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL9741792 | 0.98 | P2RX7 (0.44) | P2RX7OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL10286357 | 0.95 | P2RX7 (0.45) | P2RX7OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL1514902 | 0.95 | P2RX7 (0.45) | P2RX7OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL29472109 | 0.95 | P2RX7 (0.45) | P2RX7OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL5021376 | 0.95 | P2RX7 (0.45) | P2RX7OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL3314142 | 0.87 | OPRL1 (0.49) | P2RX7OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL17549915 | 0.87 | OPRL1 (0.49) | P2RX7OPRL1KCNH2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| WO-2018081612-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ACTAVALON, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | ANORMED, INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-8778967-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-8546410-B2 | Heteroaryl-fused macrocyclic pyrimidine derivatives | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2006-05-11 | — | — | US | disclosed |
| WO-2006028896-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1465889-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | AnorMED Inc. (CA) | 2004-10-13 | — | — | EP | disclosed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003055876-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2003-07-10 | — | — | WO | disclosed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | P2RX7 196/4885OPRL1 86/4885KCNH2 4312/4885 |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | P2RX7 196/4885OPRL1 86/4885KCNH2 4312/4885 |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | P2RX7 196/4885OPRL1 86/4885KCNH2 4312/4885 |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | CCR5, CXCR4, CXCR3 | P2RX7 196/4885OPRL1 86/4885KCNH2 4312/4885 |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | P2RX7 445/4885OPRL1 3991/4885KCNH2 2160/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | P2RX7 196/4885OPRL1 86/4885KCNH2 4312/4885 |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | P2RX7 196/4885OPRL1 86/4885KCNH2 4312/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | P2RX7 196/4885OPRL1 86/4885KCNH2 4312/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | P2RX7 142/4885OPRL1 75/4885KCNH2 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.